Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-12 pm EST			5-day change	1st Jan Change
31.86 ^USD	-1.33%		-8.76%	-1.36%

Oct. 30	Harmony Biosciences Holdings Launches Secondary Common Stock Offering	MT
Oct. 29	Harmony Biosciences Holdings, Inc., Q3 2024 Earnings Call, Oct 29, 2024

Presentation Operator MessageOperator (Operator)Good morning...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings Launches Secondary Common Stock Offering	Oct. 30	MT
Harmony Biosciences Holdings, Inc., Q3 2024 Earnings Call, Oct 29, 2024	Oct. 29
Harmony Biosciences Holdings Q3 Adjusted Earnings, Net Product Revenue Increase	Oct. 29	MT
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	Oct. 29	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Oct. 29	CI
Harmony Biosciences Holdings, Inc. Re-Iterates Revenue Guidance for the Full Year 2024	Oct. 29	CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Reports Q3 EPS $1.03	Oct. 29	MT
Harmony Biosciences Holdings, Inc. - Analyst/Investor Day	Oct. 01
Harmony Biosciences Boosted by Narcolepsy Treatment, Diversification Outlook. UBS Says	Sep. 10	MT
UBS Initiates Harmony Biosciences Holdings at Buy With $56 Price Target	Sep. 10	MT
Mizuho Securities Adjusts Harmony Biosciences Price Target to $42 From $40, Maintains Outperform Rating	Aug. 07	MT
Harmony Biosciences' Q2 Adjusted EPS, Revenue Rise; Shares Gain	Aug. 06	MT
Harmony Biosciences Holdings, Inc., Q2 2024 Earnings Call, Aug 06, 2024	Aug. 06
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	Aug. 06	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 06	CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q2 EPS $0.20, vs. Street Est of $0.12	Aug. 06	MT
Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024	Aug. 06	CI
Harmony Biosciences Holdings, Inc. Announces Resignation of Jack Bech Nielsen from Board	Jul. 01	CI
Harmony Biosciences Holdings, Inc. Announces U.S. Food & Drug Administration Action Deny the Citized Petition for WAKIX®?	Jun. 25	CI
Harmony Biosciences Says FDA Approves Supplemental NDA for Pediatric Narcolepsy Treatment	Jun. 24	MT
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX in Pediatric Patients with Narcolepsy	Jun. 24	CI
Citigroup Initiates Harmony Biosciences at Buy Rating With $48 Price Target	Jun. 21	MT
Harmony Biosciences Holdings, Inc. Reaffirms Sales Guidance for the Year 2024	Jun. 10	CI
Harmony Biosciences Holdings, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM	Jun. 10
HARMONY Biosciences Presents Positive Data for Pitolisant in the Treatment of Excessive Daytime Sleepiness and FATIGUE in Myotonic Dystrophy Type 1	Jun. 05	CI